新型聚合物在头颈鳞癌动物模型中的应用
该实验动物研究在部分切除的头颈鳞癌小鼠模型中评估了负载顺铂和CCL21的聚合物平台的不良反应和疗效,并评估了顺铂聚合物与放疗联合的效果及生物相容性。结果显示各聚合物组均显著缩小肿瘤,顺铂聚合物联合放疗较单纯高剂量放疗进一步减瘤,组织病理学未见明显毒性或炎症。
要点
- 顺铂、CCL21及双药聚合物均显著缩小SCCVII/SF小鼠肿瘤。
- 顺铂聚合物联合放疗较单纯高剂量放疗进一步减瘤。
- 组织病理学未见明显毒性或炎症,支持开展临床试验。
核心结论
- 顺铂、CCL21及顺铂/CCL21双药聚合物均具有显著抗肿瘤效果并降低肿瘤负荷。
- 顺铂聚合物联合放疗可能允许降低已接受顺铂聚合物患者的放疗强度。
- 组织病理学分析提示该聚合物在此模型中无显著不良反应,值得开展临床试验。
研究设计与样本
- 实验动物研究,学术研究实验室。
- 通过SCCVII/SF细胞注射在C3H/HeJ小鼠建立头颈鳞癌肿瘤,行手术并在切除部位植入聚合物。
- 接受顺铂治疗的受试者分为放疗或不放疗,8周后取材评估聚合物生物相容性。
主要发现
- 与对照相比,顺铂聚合物显著缩小SCCVII/SF肿瘤49%±8.7%(Δ3.4±0.6 cm3,95%CI,P<.05)。
- CCL21聚合物缩小肿瘤42%±4.8%(Δ3.5±0.4 cm3)。
- 顺铂/CCL21双药聚合物缩小肿瘤82%±4.4%(Δ8.0±0.4 cm3)。
- 顺铂聚合物联合高剂量(16 Gy)放疗减瘤92%±7.2%(Δ6.1±0.5 cm3),联合低剂量(4 Gy)放疗减瘤85%±7.4%(Δ5.7±0.5 cm3),均优于单纯高剂量放疗的70%±7.9%(Δ4.7±0.5 cm3)。
- 放疗联合顺铂聚合物治疗后组织病理学未见显著毒性或炎症。
关键数值与推荐
- 顺铂聚合物组肿瘤缩小49%±8.7%(Δ3.4±0.6 cm3,95%CI,P<.05)。
- CCL21聚合物组肿瘤缩小42%±4.8%(Δ3.5±0.4 cm3)。
- 双药聚合物组肿瘤缩小82%±4.4%(Δ8.0±0.4 cm3)。
- 顺铂聚合物+16 Gy放疗减瘤92%±7.2%(Δ6.1±0.5 cm3);+4 Gy放疗减瘤85%±7.4%(Δ5.7±0.5 cm3);单纯16 Gy放疗减瘤70%±7.9%(Δ4.7±0.5 cm3)。
临床怎么用
- 在部分切除的头颈鳞癌模型中,局部植入顺铂/CCL21聚合物可显著减瘤且生物相容性良好。
- 顺铂聚合物联合放疗可增强减瘤效果,可能为降低放疗强度提供实验依据。
- 结果支持进一步开展临床试验评估该聚合物平台。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective To evaluate the adverse effects and therapeutic efficacy of our biocompatible polymer platform delivering targeted local therapy of cytokine CCL21 and cisplatin in a partially resected xenograft animal model of head and neck squamous cell carcinoma. In addition, to evaluate the efficacy of cotreatment with radiotherapy and assess the biocompatibility of the cisplatin-eluting polymer in the murine neck. Study Design Experimental animal study. Setting Academic research laboratory. Subjects and Methods SCCVII/SF cell injection established head and neck squamous cell carcinoma tumors in C3H/HeJ mice. Subjects underwent surgery, and a chemokine-eluting polymer was implanted into the resected site. Subjects treated with cisplatin received radiation or no radiation, and tissue was harvested after 8 weeks to assess polymer biocompatibility. Results Our results with the polymer platform significantly ( P < .05) reduced SCCVII/SF tumor size in C3H/HeJ mice with cisplatin (49% ± 8.7%, Δ3.4 ± 0.6 cm3 [95% CI]), CCL21 (42% ± 4.8%, Δ3.5 ± 0.4 cm3), and cisplatin/CCL21 dual-agent polymer (82% ± 4.4%, Δ8.0 ± 0.4 cm3) as compared with controls. Cisplatin polymer with high-dose (16 Gy) and low-dose (4 Gy) radiation reduced tumor mass (respectively, 92% ± 7.2%, Δ6.1 ± 0.5 cm3; 85% ± 7.4%, Δ5.7 ± 0.5 cm3) as compared with the reduction from high-dose radiotherapy alone (70% ± 7.9%, Δ4.7 ± 0.5 cm3). No significant toxicity or inflammation was noted on histopathology after radiotherapy and cisplatin-eluting polymer treatment. Conclusion Cisplatin, CCL21, and cisplatin/CCL21 dual-agent polymer all exhibit significant antitumor effects and decrease tumor burden. Moreover, combination cisplatin polymer with radiotherapy may permit a decrease in intensity of radiation therapy in patients having received the cisplatin polymer. Histopathologic analysis suggests that the polymer is free from significant adverse effects in this model and warrants clinical trial.
引用
- Pellionisz PA, Lin Y, Mallen-St Clair J, et al. Use of a Novel Polymer in an Animal Model of Head and Neck Squamous Cell Carcinoma. Otolaryngol Head Neck Surg. 2017. PMID: 28895464. doi:10.1177/0194599817730304
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。